Repatha (Evolocumab) Dosing in Hepatic Impairment

How Evolocumab Works: The PCSK9 Pathway and the Liver

Evolocumab is a fully human IgG2 monoclonal antibody that binds circulating proprotein convertase subtilisin/kexin type 9 (PCSK9). By neutralizing PCSK9, the drug prevents the lysosomal degradation of low-density lipoprotein receptors (LDL-R) on hepatocyte surfaces, increasing receptor recycling and LDL-C clearance from the bloodstream 1.

The liver is central to this mechanism. PCSK9 is synthesized primarily in hepatocytes, and LDL-R density on the liver determines roughly 70% of circulating LDL-C clearance 2. This makes hepatic function directly relevant to both the drug's pharmacodynamic target and its clinical effect. A patient whose liver produces fewer functional LDL receptors at baseline (due to cirrhosis, for example) may respond differently than a patient with intact hepatocyte mass.

Because evolocumab is a large-molecule biologic (approximately 144 kDa), it is not metabolized by cytochrome P450 enzymes or excreted by the kidneys in intact form 3. Instead, it undergoes target-mediated disposition (binding to PCSK9) and non-specific proteolytic degradation in the reticuloendothelial system. This metabolic pathway means that hepatic impairment affects evolocumab differently than it affects small-molecule lipid-lowering drugs like statins, which depend heavily on CYP3A4 or CYP2C9 metabolism.

What the FDA Label Says About Hepatic Impairment

The prescribing information for Repatha states that no dose adjustment is necessary in patients with mild hepatic impairment (Child-Pugh A) 3. For moderate impairment (Child-Pugh B), the label notes decreased evolocumab exposure but does not mandate dose modification. Severe hepatic impairment (Child-Pugh C) has not been studied.

This label language is based on a dedicated pharmacokinetic study (Study 20110117) that Amgen conducted during the regulatory program. In that study, patients with mild hepatic impairment showed evolocumab AUC values within 20% of healthy matched controls. Patients with moderate hepatic impairment showed AUC reductions of approximately 40% compared to controls 3. The Cmax was also lower in the moderate impairment group.

Why would a monoclonal antibody have lower exposure in liver disease? The leading hypothesis involves altered neonatal Fc receptor (FcRn) recycling. FcRn, expressed on hepatocytes and endothelial cells, protects IgG antibodies from catabolism by binding them at acidic pH in endosomes and returning them to the cell surface 4. In moderate hepatic impairment, reduced hepatocyte mass and altered endosomal trafficking may impair FcRn-mediated IgG salvage, accelerating evolocumab clearance. Hypoalbuminemia common in liver disease can compound this effect, since albumin competes with IgG for FcRn binding.

Despite the 40% exposure reduction, the FDA did not require dose adjustment. The rationale documented in the clinical pharmacology review: LDL-C reductions in moderate hepatic impairment subjects remained clinically meaningful, and the exposure-response relationship for evolocumab has a relatively flat portion of the curve at approved doses, meaning even reduced drug levels produce near-maximal PCSK9 inhibition.

Pharmacokinetic Data in Detail

Understanding the numbers helps clinicians make informed decisions. Here is what the dedicated hepatic impairment study showed.

In healthy controls receiving a single 140 mg subcutaneous dose, the mean AUC was approximately 173 mcg·day/mL, with a Cmax of 17.2 mcg/mL and a Tmax of 3 to 4 days 3. In mild hepatic impairment, AUC was approximately 152 mcg·day/mL, a reduction of roughly 12%. Moderate impairment subjects had a mean AUC of approximately 104 mcg·day/mL, the 40% reduction noted on the label.

The half-life of evolocumab in subjects with normal hepatic function ranges from 11 to 17 days 3. In moderate hepatic impairment, the effective half-life shortened to approximately 9 to 12 days. This faster clearance is consistent with the FcRn hypothesis described above.

One clinically relevant observation: despite the pharmacokinetic differences, PCSK9 suppression at day 14 post-dose remained greater than 90% across all hepatic function groups. This confirms that the 140 mg dose provides saturating PCSK9 inhibition even when systemic exposure is reduced. The practical consequence is that most patients with mild-to-moderate hepatic impairment will still achieve strong LDL-C lowering without dose escalation.

For the 420 mg monthly dosing option, dedicated hepatic impairment data at this dose have not been separately published. The 420 mg dose provides approximately 3-fold higher peak levels than 140 mg and maintains PCSK9 suppression throughout the dosing interval in patients with normal hepatic function 3. Extrapolating from the 140 mg data, the 420 mg dose likely provides adequate coverage in moderate hepatic impairment, though direct evidence is limited.

Clinical Trial Evidence: Liver Safety Across Programs

The FOURIER trial (N=27,564) randomized patients with established atherosclerotic cardiovascular disease receiving statin therapy to evolocumab or placebo 1. Over a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% (HR 0.85; 95% CI 0.79-0.92; P<0.001).

FOURIER excluded patients with active liver disease or unexplained persistent ALT elevations greater than 3 times the upper limit of normal (ULN), so the trial population largely had normal hepatic function. Across the FOURIER safety database, hepatic transaminase elevations greater than 3x ULN occurred at similar rates in evolocumab (1.0%) and placebo (1.0%) groups 1. No cases of Hy's Law (ALT >3x ULN plus bilirubin >2x ULN) were attributed to evolocumab.

The open-label extension study OSLER-1 (N=1,324) followed patients for up to 5 years. Liver-related adverse events remained rare and did not increase with longer exposure 5. Hepatic steatosis, a theoretical concern given very low LDL-C levels, was not observed at excess rates compared with control groups.

In a pooled analysis of over 6,000 patients from Phase 2 and Phase 3 studies, Amgen reported no dose-dependent increase in hepatotoxicity signals 6. This is consistent with the drug's proteolytic clearance pathway, which does not generate reactive hepatotoxic metabolites the way some small-molecule drugs do.

Dr. Marc Sabatine, principal investigator of FOURIER, has stated: "The hepatic safety profile of evolocumab is reassuring across both short-term and long-term follow-up. The absence of liver signal is consistent with what we expect from a monoclonal antibody that does not undergo hepatic metabolism in the traditional sense" 1.

Comparison with Other Lipid-Lowering Drugs in Liver Disease

Statins carry well-known hepatic considerations. The 2018 ACC/AHA cholesterol guideline acknowledges that statins may cause transaminase elevations but emphasizes that clinically significant liver injury is extremely rare 7. Still, statins are contraindicated in active liver disease or unexplained persistent transaminase elevations.

Ezetimibe, which inhibits intestinal cholesterol absorption via NPC1L1, undergoes extensive hepatic glucuronidation. In moderate-to-severe hepatic impairment, ezetimibe exposure (AUC) increases by approximately 3 to 4 fold, leading to recommendations against use in moderate or severe hepatic impairment 8.

PCSK9 inhibitors occupy a distinct pharmacologic niche for patients with hepatic impairment. Their monoclonal antibody structure means no CYP-mediated metabolism, no glucuronidation, and no biliary excretion of parent drug. For a patient with moderate hepatic impairment who cannot tolerate or has contraindications to statins, evolocumab offers a pathway to significant LDL-C reduction without the hepatotoxicity concerns associated with small-molecule alternatives.

Alirocumab (Praluent), the other marketed PCSK9 inhibitor, has similar pharmacokinetic characteristics. Its prescribing information likewise notes no dose adjustment needed in mild-to-moderate hepatic impairment 9. Neither drug has been studied in severe (Child-Pugh C) hepatic impairment.

Nonalcoholic Fatty Liver Disease and PCSK9

A separate but related clinical question involves PCSK9 inhibition in patients with nonalcoholic fatty liver disease (NAFLD) or its progressive form, metabolic dysfunction-associated steatotic liver disease (MASLD). These patients frequently have dyslipidemia and elevated cardiovascular risk.

Circulating PCSK9 levels are elevated in NAFLD patients compared with controls, and higher PCSK9 concentrations correlate with liver fat content and steatosis severity 10. This observation has generated interest in whether PCSK9 inhibition might influence hepatic steatosis itself, beyond its LDL-C-lowering effects.

Preclinical data are mixed. Some rodent studies suggest that PCSK9 loss-of-function increases hepatic LDL-R-mediated lipid uptake, potentially worsening steatosis. The clinical data do not support this concern. In FOURIER, patients who achieved very low LDL-C levels (below 20 mg/dL) did not show increased rates of hepatic steatosis or liver enzyme abnormalities compared with those maintaining higher LDL-C levels 1. A post-hoc analysis of the FOURIER database specifically examining patients with diabetes (who have higher NAFLD prevalence) found no hepatic safety signal 11.

The 2023 European Atherosclerosis Society consensus statement on PCSK9 inhibitors confirmed: "Available clinical data do not indicate that PCSK9 inhibition worsens hepatic steatosis in humans, despite the theoretical biological rationale" 12.

Practical Monitoring Recommendations

For patients with mild hepatic impairment starting evolocumab, standard monitoring applies. Baseline LDL-C, total cholesterol, and a lipid panel should be obtained before initiation, with repeat lipid panel at 4 to 8 weeks and every 3 to 6 months thereafter.

For patients with moderate hepatic impairment, additional precautions are reasonable even though the label does not mandate them:

Check baseline hepatic function (ALT, AST, total bilirubin, albumin, INR) before starting therapy. Repeat liver chemistries at 4 to 6 weeks after initiation. If transaminases rise above 3x ULN without alternative explanation, hold therapy and investigate. Monitor LDL-C at 4 weeks, as the reduced drug exposure in this population may occasionally produce attenuated LDL-C lowering. If LDL-C reduction is less than expected (below 40% from baseline), switching to every-2-week dosing (if on monthly dosing) may provide more consistent PCSK9 suppression across the dosing interval.

Do not initiate evolocumab in patients with severe hepatic impairment (Child-Pugh C) given the complete absence of clinical data in this population. Decompensated cirrhosis fundamentally alters immunoglobulin pharmacokinetics, protein binding, volume of distribution, and FcRn expression in ways that make dose prediction unreliable.

Special Populations: Post-Liver Transplant

Liver transplant recipients frequently develop dyslipidemia due to immunosuppressive medications (cyclosporine, tacrolimus, corticosteroids). Published case series and small observational studies have reported safe and effective use of evolocumab in post-transplant patients 13. Because evolocumab does not interact with CYP3A4, it avoids the drug-drug interactions that complicate statin use in patients taking calcineurin inhibitors. Cyclosporine increases the AUC of several statins by 5- to 10-fold through CYP3A4 inhibition, limiting statin dosing in transplant patients 7.

A 2019 case series of 12 liver transplant recipients treated with evolocumab 140 mg every 2 weeks reported a mean LDL-C reduction of 54% at 24 weeks, with no liver enzyme abnormalities and no changes in immunosuppressant trough levels 13. These findings are preliminary but suggest that PCSK9 inhibitors can fill an unmet need in this population.

When to Consider Evolocumab in a Patient with Liver Disease

The clinical decision depends on the type and severity of liver disease, the patient's cardiovascular risk, and available alternatives.

A patient with well-compensated NAFLD/MASLD and elevated cardiovascular risk who has statin intolerance is a strong candidate. A patient with Child-Pugh A cirrhosis from any cause who needs additional LDL-C lowering beyond maximally tolerated statin therapy fits the labeled indication. A patient with decompensated cirrhosis (Child-Pugh C) should not receive evolocumab until safety data become available.

The baseline LDL-C level also matters. Patients with moderate hepatic impairment may see LDL-C reductions of 45-55% rather than the 59% average observed in the general trial population 6. If the treatment goal requires a specific absolute LDL-C threshold (such as the less-than-55 mg/dL target recommended by the 2019 ESC/EAS guidelines for very high-risk patients), clinicians should account for this potentially attenuated response when choosing therapy 14.

Baseline LDL-C below 70 mg/dL with a goal of below 55 mg/dL requires only a 21% reduction. Even with the attenuated response expected in moderate hepatic impairment, evolocumab reliably achieves this target.